A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 3RecruitingNCT05956626

Ocugen51 enrolled

Overview

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.

Name of Investigational Product: OCU410ST Name of Active Ingredient: Adeno-associated viral vector 5 human RORA (AAV5-hRORA) Title of Study: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE Study Center(s): Approximately fifteen study centers in the US. Background: Stargardt disease is an eye disease that causes vision loss in children and young adults. It is an inherited disease caused by faulty genes that cause buildup of fat deposits in the eye. Currently, there is no approved treatment available for Stargardt disease. OCU410ST Product Information: OCU410ST is an Adeno-Associated Virus serotype 5 containing human RORA for the treatment of Stargardt disease. Dysregulation in lipid metabolism, oxidative stress, and anti-inflammatory mechanisms are critical for pathogenesis and progression of Stargardt disease. The role of hRORA in regulating these gene pathways strongly suggests OCU410ST could restore homeostasis in the eye and thereby serve as a therapeutic candidate for Stargardt disease. Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study. A total of fifty-one (51) subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Treatment group: 34 subjects. Subjects will receive a single subretinal injection of 200 µL OCU410ST in concentration of 1.5×10E11 vg/mL. Control group: 17 subjects. Subjects who are enrolled in the untreated control group of the study will not receive any treatment. They will be followed according to the same treatment schedule as the treated subjects. Note: Data will be collected for the untreated eye at Screening, 4-month, 8-month, 12-month, four (4) long-term safety follow-up visits, and early termination visit (if applicable). Data will be collected for the treated eye at Screening, treatment Day 1, Day 2, Day 15, 4-month, 8-month, 12-month, four (4) long-term safety follow-up visits, and early termination visit (if applicable). Enrollment in the Phase 1 study is complete. Phase 1 enrolled a total of nine subjects in low, medium and high dose cohorts. Low Dose Cohort (3.75×10E10 vg/mL): Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in low dose concentration (3.75×10E10 vg/mL). Medium Dose Cohort (7.5×10E10 vg/mL): Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in medium dose concentration (7.5×10E10 vg/mL). High Dose Cohort (2.25×10E11 vg/mL): Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in high dose concentration (2.25×10E11 vg/mL).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Stargardt Disease

Interventions

OCU410STDRUG

Subretinal Administration of OCU410ST

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Phase 2/3 Inclusion Criteria (applicable for both adult and pediatric subjects): 1. Males or females aged ≥5 years at the time of consent. 2. Subjects who have confirmed clinical and CLIA certified or equivalent genetic diagnosis of Stargardt disease (including ABCA4 related retinopathies). 3. Adult subjects who have BCVA of 75 letters or less in the study eye (20/32 Snellen equivalent) and Pediatric subjects who have a BCVA of 35 letters or better in the study eye (20/200 Snellen equivalent). 4. The study eye should have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns, and total lesion size must add to less than or equal to ≤ 18 mm2 (approximately 7-disc areas). 5. Have detectable outer nuclear layer (ONL) in the macular region Phase 2/3 Exclusion Criteria (applicable for both adult and pediatric subjects): 1. Participation in ongoing antiretroviral therapy treatment. 2. Participation in any experimental treatment or research study within 60 days before screening (any previous eye treatments involving gene therapy, stem cells, implanted retinal chips, injections into the eye, or participation in an Alkeus ALK-001 study within the past 6 months) 3. Macular atrophy secondary to any disease other than Stargardt Disease (STGD). 4. Presence of genetic mutations that mimic Stargardt Disease like ELOVL4, or PROM1. 5. Contraindication to subretinal injection or use of anesthesia (local and/or general). Phase 1 was a multicenter, open-label, dose-ranging/dose escalation study. Enrollment is complete for Phase 1

Locations (14)

Associated Retina Consultants

Phoenix, Arizona, United States

RECRUITING

Retinal Consultants Medical Group

Sacramento, California, United States

Outcomes

Primary Outcomes

Change from baseline in atrophic lesion size as measured by Fundus Auto Fluorescence

Change in the area of atrophy will be evaluated from the baseline measurements, using FAF to assess the loss of retinal layers.

Time frame: 12 months (Screening to 12 months post OCU410ST administration)

Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))

Safety will be determined by the number of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

Time frame: 12 months (Screening to 12 months post OCU410ST administration)

Secondary Outcomes

Change from baseline in Low Luminance Visual Acuity (LLVA)

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual Acuity (LLVA) letter score. A higher score represents better vision.

Time frame: 12 months (Screening to 12 months post OCU410ST administration)

Change from baseline in Best Corrected Visual Acuity (BCVA)

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.

Time frame: 12 months (Screening to 12 months post OCU410ST administration)

Central Contacts

Umair Qazi, MD, MPH

CONTACT

+1 (202)-817-0787 umair.qazi@ocugen.com

Mahvish Tafseer, MD, MPH

CONTACT

484-224-3409 mahvish.tafseer@ocugen.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.